$RARE· SEC filing ·

RARE Announces Positive Phase 3 DTX301 Data: 18% Ammonia Reduction, 71% Much Improved, $150M Spend

Ultragenyx Pharmaceutical Inc. · PHARMACEUTICAL PREPARATIONS · Now $23.94

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS